Federated Hermes’s Annovis Bio ANVS Stock Holding History

Federated Hermes’s Portfolio ANVS Stock Details ANVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-19	Closed	-$2K	–	2207
2021 Q2	$2K	Buy	+19	New	+$878	﹤0.01%	2093

Other funds holding ANVS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

WFAG

Wescott Financial Advisory Group Philadelphia, Pennsylvania $1.14B AUM 16.59% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Federated Hermes's ANVS Position: Q3 2021 in Review

Federated Hermes sold out of Annovis Bio (ANVS) in Q3 2021, closing a stake of 19 shares — an estimated $2K sold.

Federated Hermes first reported a position in ANVS in Q2 2021 and held it in 1 quarter. The position peaked at $2K in Q2 2021. 38 funds tracked by Wall St. Rank hold ANVS as of Q3 2021.

Federated Hermes reported no remaining Annovis Bio position as of Q3 2021 after selling out during the quarter.
Federated Hermes sold 19 Annovis Bio shares in Q3 2021, an estimated $2K.
Federated Hermes first reported a position in Annovis Bio in Q2 2021 and held it in 1 quarter.
Federated Hermes's Annovis Bio position peaked at $2K in Q2 2021.
38 funds tracked by Wall St. Rank held Annovis Bio as of Q3 2021.

Based on Federated Hermes's 13F filing for Q3 2021, filed 15 Nov 2021.